News | Oncology Related Products | March 31, 2016

The History and Future of Cancer Immunotherapy

Imaging will continue to be used for response assessment as new therapies continue to develop

cancer immunotherapy, development, Axel Hoos, Nature Reviews, imaging

March 31, 2016 — In a paper published in Nature Reviews last week, Axel Hoos, M.D., Ph.D., laid out the current immunotherapy development paradigm, as well as his strategic vision to optimize the implementation of next-generation immunotherapies.

Immunotherapy is currently revolutionizing cancer treatment and, according to Axel Hoos, M.D., Ph.D., has the potential to improve patient outcomes significantly in the future. Hoos leads one of the Cancer Research Institute’s (CRI) programs — the Cancer Immunotherapy Consortium (CIC) — that played an important role in enabling early immunotherapy trials to succeed.

Imaging is often used to monitor patient response to this therapy, but there is difficulty in measuring treatment response because it presents very differently than traditional chemotherapy response. The tumors sometimes increase in size for a couple of months before the treatment begins to shrink tumors over time. The tumor tissue response is also often delayed and may be mistaken as ineffective in the first couple months of monitoring.

Under the leadership of Hoos, who also serves as GlaxoSmithKline’s head of immuno-oncology, the CIC initiatives highlighted how two important factors were complicating immunotherapy trials. First, immunotherapy can produce novel responses that are not accounted for in the traditional response criteria developed for chemotherapy. Second, immunotherapy’s differential effects on clinical endpoints, such as survival, need to be addressed. In addition to the development of new immune-related response criteria (irRC), Hoos also believes that the CIC’s insights helped to transform the development program for the first checkpoint blockade immunotherapy drug, the anti-CTLA-4 antibody ipilimumab (Yervoy), which unleashes the immune system and enables a stronger anti-cancer response.

With the help of the new immunotherapy-related criteria, early trials employing ipilimumab as well as other checkpoint blockade drugs, such as the anti-PD-1 antibody pembrolizumab (Keytruda) and nivolumab (Opdivo), paved the way for immunotherapy to improve the standard of care in cancer treatment. Furthermore, these stimulated cooperative efforts in the immunotherapy community that directly influenced the regulatory guidance documents of both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

Moving forward, Hoos hopes that the CIC, which has since been reconstituted as an industry advisory “think tank” focused on late-stage drug development, can build on these accomplishments. According to him, several factors will drive the efforts to usher in the next generation of immunotherapies — including technologies such as cancer vaccines, re-engineered oncolytic viruses and cell-based therapies — as well as to maximize the benefits of current immune-based drugs:

  • First, immunotherapy has already started to change the standard of care in oncology, both in significant improvements in survival as well as side effects. This will substantially change the treatment landscape and will require careful integration of immunotherapies into current treatment strategies as new information becomes available;
  • Second, there is still room to improve the criteria by which clinicians can determine successful patient responses to immunotherapy;
  • Third, not all patients respond to the same treatment the same way. To ensure each patient receives the most beneficial treatment for their particular tumors, better immune biomarkers must be developed;
  • Fourth, while individual immunotherapies have already produced clinical improvements, early trials with combination therapies suggest that benefits can be improved. Determining rational strategies for combination therapies will be a high priority moving forward; and
  • Fifth, novel immunotherapy technologies already present much promise, and by incorporating recent scientific breakthroughs into the design of treatments, their effectiveness will continue to improve patient outcomes in the future.

Immunotherapy was declared the Breakthrough of the Year by Science in 2013. To ensure that immunotherapy realizes its full potential, much more must be learned about the immune system, cancer, and their interactions within the complex and ever-changing tumor environments of individual patients.

For more information: www.nature.com/reviews

Related Content

Black Men Less Likely to Adopt Active Surveillance for Low-Risk Prostate Cancer
News | Prostate Cancer | June 17, 2019
A new study reveals black men are less likely than white men to adopt an active surveillance strategy for their...
International Working Group Releases New Multiple Myeloma Imaging Guidelines

X-ray images such as the one on the left fail to indicate many cases of advanced bone destruction caused by multiple myeloma, says the author of new guidelines on imaging for patients with myeloma and related disorders. Image courtesy of Roswell Park Comprehensive Cancer Center.

News | Computed Tomography (CT) | June 17, 2019
An International Myeloma Working Group (IMWG) has developed the first set of new recommendations in 10 years for...
Sectra Providing Centralized Regional Solution for Digital Pathology in the U.K.
News | Digital Pathology | June 14, 2019
Sectra has signed a five-year contract with North Tees and Hartlepool National Health System (NHS) Foundation Trust for...
Sponsored Content | Videos | Radiology Imaging | June 13, 2019
In an interview with itnTV, Henry Izawa, vice president, modality solutions and clinical affairs, Fujifilm Medical Sy
A static image drawn from a stack of brain MR images may illustrate the results of a study. But a GIF (or MP4 movie), created by the Cinebot plug-in, can scroll through that stack, providing teaching moments for residents and fellows at Georgetown University

A static image drawn from a stack of brain MR images may illustrate the results of a study. But a GIF (or MP4 movie), created by the Cinebot plug-in, can scroll through that stack, providing teaching moments for residents and fellows at Georgetown University. Image courtesy of MedStar Georgetown University Hospital

Feature | Information Technology | June 13, 2019 | By Greg Freiherr
Editor’s note: This article is the third in a content series by Greg Freiherr covering the Society for Imaging In
At ACC 2019, Siemens unveiled a version of its go.Top CT optimized for cardiovascular imaging. The newly packaged scanner can generate data needed to do  CT-based FFR (fractional flow reserve).

At ACC 2019, Siemens unveiled a version of its go.Top CT optimized for cardiovascular imaging. The newly packaged scanner can generate data needed to do
CT-based FFR (fractional flow reserve).

Feature | Cardiac Imaging | May 31, 2019 | By Greg Freiherr
The fingerprints of value-added medicine were all over products and works-in-progress on the exhibit floor of the ann
Einstein Healthcare Network found that use of automated power injectors reduced CT contrast extravasation rates over a 30-month period.

Einstein Healthcare Network found that use of automated power injectors reduced CT contrast extravasation rates over a 30-month period.

Feature | Computed Tomography (CT) | May 30, 2019 | By Jeff Zagoudis
As of 2015, approximately 79 million computed tomography (CT) scans were performed each year in the U.S.
Sponsored Content | Webinar | Computed Tomography (CT) | May 30, 2019
This webinar will explain technical considerations when performing cardiac CT angiography in pediatric patients.
Sponsored Content | Webinar | Computed Tomography (CT) | May 30, 2019
Chest pain is one of the most frequent reasons for an evaluation in the emergency room.There are multiple imaging mod
Vast Majority of Heavy Smokers Not Screened for Lung Cancer
News | Lung Cancer | May 29, 2019
Out of more than 7 million current and former heavy smokers, only 1.9 percent were screened for lung cancer in 2016...